Suven Pharmaceuticals Limited (SUVENPHAR) — Cash Flow-to-Debt Ratio
Suven Pharmaceuticals Limited (SUVENPHAR) has a Cash Flow-to-Debt Ratio of 0.33x as of December 2023, meaning its operating cash flow of Rs255.04 Million could theoretically repay 0% of its total liabilities (Rs765.00 Million) in one year. See Suven Pharmaceuticals Limited free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Suven Pharmaceuticals Limited Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for Suven Pharmaceuticals Limited across 7 annual periods. For the full cash flow conversion analysis, see SUVENPHAR cash generation efficiency.
Annual Cash Flow-to-Debt Ratio for Suven Pharmaceuticals Limited (2019–2025)
Year-by-year debt coverage analysis for Suven Pharmaceuticals Limited. Check Suven Pharmaceuticals Limited (SUVENPHAR) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (INR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.24x | Rs2.88 Billion | Rs11.91 Billion | ▼ -86.3% |
| 2024 | 1.76x | Rs3.58 Billion | Rs2.03 Billion | ▼ -9.9% |
| 2023 | 1.96x | Rs4.51 Billion | Rs2.31 Billion | ▲ +79.2% |
| 2022 | 1.09x | Rs3.30 Billion | Rs3.02 Billion | ▼ -16.4% |
| 2021 | 1.31x | Rs3.83 Billion | Rs2.94 Billion | ▲ +3.0% |
| 2020 | 1.27x | Rs4.16 Billion | Rs3.28 Billion | ▲ +384.8% |
| 2019 | 0.26x | Rs504.05 Million | Rs1.93 Billion | — |